Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Adam Mostafa Biography and Net Worth

CFO of X4 Pharmaceuticals

Mr. Mostafa has served as X4’s Chief Financial Officer since September 2018. Prior to joining X4, Mr. Mostafa served as chief financial officer of Abpro Corporation, a biotechnology company focused on antibody therapeutics. Prior to that, Mr. Mostafa was a managing director in the healthcare investment banking group at Cantor Fitzgerald, and was a senior banker in the healthcare investment banking group at Needham & Company. Prior to that, Mr. Mostafa was a vice president in the investment banking group at CRT Capital Group, and was a portfolio management associate in the global stock selection group at AQR Capital. He began his career as an analyst in the healthcare investment banking group at Salomon Smith Barney. Mr. Mostafa earned an A.B. in Economics from Brown University.

What is Adam S. Mostafa's net worth?: The estimated net worth of Adam S. Mostafa is at least $32,025.00 as of February 12th, 2024. Mr. Mostafa owns 52,500 shares of X4 Pharmaceuticals stock worth more than $32,025 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Mostafa may own. Additionally, Mr. Mostafa receives an annual salary of $700,780.00 as CFO at X4 Pharmaceuticals. Learn More about Adam S. Mostafa's net worth.
How old is Adam S. Mostafa?: Mr. Mostafa is currently 44 years old. There are 8 older executives and no younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals is Dr. Robert David Arbeit, Senior Vice President of Clinical Development and Translational Research, who is 76 years old. Learn More on Adam S. Mostafa's age.
What is Adam S. Mostafa's salary?: As the CFO of X4 Pharmaceuticals, Inc., Mr. Mostafa earns $700,780.00 per year. The highest earning executive at X4 Pharmaceuticals is Dr. Paula Ragan Ph.D., CEO, President & Director, who commands a salary of $1,010,000.00 per year. Learn More on Adam S. Mostafa's salary.
How do I contact Adam S. Mostafa?: The corporate mailing address for Mr. Mostafa and other X4 Pharmaceuticals executives is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. X4 Pharmaceuticals can also be reached via phone at (857) 529-8300 and via email at [email protected]. Learn More on Adam S. Mostafa's contact information.
Has Adam S. Mostafa been buying or selling shares of X4 Pharmaceuticals?: Within the last three months, Adam S. Mostafa has sold $126,854.75 in X4 Pharmaceuticals stock. Most recently, Adam S. Mostafa sold 230,645 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.55, for a transaction totalling $126,854.75. Learn More on Adam S. Mostafa's trading history.
Who are X4 Pharmaceuticals' active insiders?: X4 Pharmaceuticals' insider roster includes Derek Meisner (General Counsel), Adam Mostafa (CFO), and Paula Ragan (CEO). Learn More on X4 Pharmaceuticals' active insiders.
Are insiders buying or selling shares of X4 Pharmaceuticals?: During the last twelve months, insiders at the sold shares 13 times. They sold a total of 766,508 shares worth more than $491,874.90. The most recent insider tranaction occured on October, 15th when CEO Paula Ragan sold 31,897 shares worth more than $17,862.32. Insiders at X4 Pharmaceuticals own 1.6% of the company. Learn More about insider trades at X4 Pharmaceuticals.
Information on this page was last updated on 10/15/2024.

Adam S. Mostafa Insider Trading History at X4 Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/7/2024	Sell	230,645	$0.55	$126,854.75
3/11/2024	Sell	52,500	$0.88	$46,200.00
2/12/2024	Sell	27,721	$1.01	$27,998.21	52,500
11/1/2023	Sell	230,645	$0.73	$168,370.85	80,221
6/30/2023	Sell	2,641	$1.89	$4,991.49	80,221
6/23/2023	Sell	5,417	$1.93	$10,454.81	82,862
6/15/2023	Sell	5,417	$2.22	$12,025.74	88,279
2/13/2023	Sell	27,721	$0.93	$25,780.53	146,196
8/17/2021	Sell	10,832	$5.10	$55,243.20
6/30/2021	Sell	2,641	$6.64	$17,536.24
6/24/2021	Sell	5,417	$7.01	$37,973.17	139,835
6/15/2021	Sell	5,417	$7.84	$42,469.28	129,002
9/21/2020	Sell	10,834	$7.08	$76,704.72
6/30/2020	Sell	1,725	$9.04	$15,594.00	8,839

Adam S. Mostafa Buying and Selling Activity at X4 Pharmaceuticals

X4 Pharmaceuticals Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $0.61

$0.57

$0.68

50 Day Range

MA: $0.50

$0.28

$0.76

2 Week Range

Now: $0.61

$0.26

$1.60

Volume

3,325,194 shs

Average Volume

2,449,592 shs

Market Capitalization

$104.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Adam Mostafa Biography and Net Worth

What is Adam S. Mostafa's net worth?

How old is Adam S. Mostafa?

What is Adam S. Mostafa's salary?

How do I contact Adam S. Mostafa?

Has Adam S. Mostafa been buying or selling shares of X4 Pharmaceuticals?

Who are X4 Pharmaceuticals' active insiders?

Are insiders buying or selling shares of X4 Pharmaceuticals?